The Effect of an Acute Increase in Plasma IL-6 on Glucose Tolerance When a Meal is Administered Intraduodenally
NCT ID: NCT03660332
Last Updated: 2024-02-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
6 participants
INTERVENTIONAL
2017-01-01
2017-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The literature provides no information regarding a role for interleukin-6 (IL-6) in the regulation of beta cell function (glucose or meal-stimulated insulin secretion) in humans. Previous studies infusing IL-6 into humans have primarily focused on insulin action and the effects on peripheral insulin sensitivity whereas a potential effect on insulin secretion has been neglected.
We have demonstrated that an acute increase in IL-6, obtained by a single bolus of IL-6, potentiated glucose-induced insulin secretion in a glucagon-like peptide-1 (GLP-1) dependent manner in mice1. In mice, IL-6 enhanced insulin secretion in a dose- and glucose-dependent manner, along with increasing concentrations of GLP-1. Interleukin-6 had no effect on insulin secretion in GLP-1 receptor knock-out mice or in mice treated with the GLP-1 receptor antagonist. Thus, in mice, GLP-1 has proven an essential mediator of IL-6 actions on beta cell function.
Importantly, a single bolus of IL-6 also significantly increased glucose-stimulated insulin secretion in several mouse models of obesity and diabetes (diet-induced obesity, the ob/ob and the db/db mouse).
Own data show that an infusion of IL-6 causes a significant delay in the rate of gastric emptying (GE) after a mixed meal in healthy young men. Data showed that this delay in GE is associated with much improved glucose tolerance and insulin secretion (unpublished data).
In the present study we wish to investigate whether the beneficial effects of IL-6 on postprandial glucose tolerance and insulin secretion are dependent on a delay in gastric emptying. We will bypass the ventricle and infuse a mixed meal directly into the duodenum of healthy young men.
This study has the potential to show that the known effect of IL-6 on postprandial glucose tolerance is dependent on a delayed GE.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Small Intestinal Endocrine Cells in Type 2 Diabetic Hyperglucagonemia
NCT00639613
Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion
NCT02010827
Glucagon Responses During Oral- and iv Glucose in Patients With Type 1 Diabetes
NCT00704795
The Anatomical Location, Cellular Origin and Molecular Basis of Gut-derived Glucagon Secretion
NCT03181191
Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 Diabetes
NCT02669524
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IL-6 infusion
Healthy young men will receive IL-6 infusion
Infusion of a liquid meal intraduodenally
Infusion of IL-6/NaCL before a liquid meal intraduodenally
Placebo infusion
Healthy young men will receive saline infusion
Infusion of a liquid meal intraduodenally
Infusion of IL-6/NaCL before a liquid meal intraduodenally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Infusion of a liquid meal intraduodenally
Infusion of IL-6/NaCL before a liquid meal intraduodenally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy (based on screening)
Exclusion Criteria
* BMI \< 18 and \> 25 kg/m2
* Evidence of severe thyroid, liver, lung, heart or kidney disease
18 Years
35 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Louise Lang Lehrskov
MD, PhD student
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bente K Pedersen, Professor
Role: STUDY_DIRECTOR
CFAS, Rigshospitalet
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rigshospitalet, Centre of Inflammation and Metabolism (CIM) Centre for Physical Activity Research (CFAS)
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lang Lehrskov L, Lyngbaek MP, Soederlund L, Legaard GE, Ehses JA, Heywood SE, Wewer Albrechtsen NJ, Holst JJ, Karstoft K, Pedersen BK, Ellingsgaard H. Interleukin-6 Delays Gastric Emptying in Humans with Direct Effects on Glycemic Control. Cell Metab. 2018 Jun 5;27(6):1201-1211.e3. doi: 10.1016/j.cmet.2018.04.008. Epub 2018 May 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-16036538
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.